Understanding how different CALR mutations drive certain blood cancers
Official title: The Pathophysiology of Type 1 Versus Type 2 Mutant Calreticulin-Drivenmyeloproliferative Neoplasms
Funded at Utah State Higher Education System--University of Utah · NIH-11393750 · Data updated 2026-11-12
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Utah State Higher Education System--University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | August 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $455,497 |
| NIH project number | 5R01HL165119-05 |
| Project ID | NIH-11393750 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with CALR-mutant myeloproliferative neoplasms may be eligible for future studies or trials related to this work.
✕Less likely to help
Patients without CALR-mutant MPNs may not benefit from these findings.
What this research studies
Researchers will study how type 1 and type 2 CALR mutations alter cell signaling and blood cell production in myeloproliferative neoplasms. The work focuses on the CALR protein’s interaction with the MPL receptor and resulting JAK/STAT signaling, seeking clues that could point to new therapies. The project is based at the University of Utah and aims to translate molecular findings into strategies that could slow disease progression for patients with PMF, ET, or PV.
Why it matters
Potential benefit: If successful, the work could identify new therapeutic targets that may slow or halt disease progression for people with CALR-mutant MPNs.
How similar studies have gone: Other CALR-focused research has begun to differentiate type 1 and type 2 mutation effects, with promising directions but no definitive cures yet.
Where this research is happening
-
Utah State Higher Education System--University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Elf, Shannon Elisabeth — Utah State Higher Education System--University of Utah
- Study coordinator: Elf, Shannon Elisabeth
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
-
Understanding how inflammation and biology drive blood cancer evolution
A large, multi-project program at Washington University is exploring how inflammatory signals and cell-intrinsic factors work together to drive progression of myeloproliferative neoplasms in people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.